Dermavant Sciences: Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting

- Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life measures, and tolerability scores with no associated tachyphylaxis - Tapinarof was well-tolerated

Related Keywords

Boston ,Massachusetts ,United States ,America ,American ,Laurence Watts ,Kostenloser Wertpapierhandel ,Aprilw Armstrong ,Angela Salerno Robin ,Philipm Brown ,Program For Tapinarof ,Twitter ,Drug Administration ,Keck School Of Medicine ,Dean For Clinical Research In Dermatology ,American Academy Of Dermatology ,Roivant Sciences ,Dermavant Sciences ,Linkedin Dermavant Sciences ,Annual Meeting ,Keck Medicine ,Associate Dean ,Clinical Research ,Keck School ,Physician Global Assessment ,Psoriasis Area ,Severity Index ,Dermatology Life Quality Index ,Chief Medical Officer ,New Drug Application ,Prescription Drug User Fee Act ,North America ,Vice President ,Media Relations ,Dermavant ,Ciences ,Howcases ,Song ,Term ,Durability ,Tolerability ,Data ,Rom ,Hase ,Soaring ,Trial ,Tapinarof ,Cream ,Adults ,Plaque ,Psoriasis ,022 ,Nnual ,Meeting ,